Boston Scientific’s Mahoney took home $11.7 million in salary and benefits in 2011
Mauna Kea Technologies
Medtronic wins Canadian approval for brain-stim therapy for epileptics | Regulatory Roundup
Ortho stocks up on strong Q2 prelims for Biomet | Earnings Roundup
Shares of orthopedic device makers are up this morning after bellwether Biomet Inc. reported preliminary sales numbers indicating 3.8% growth for its fiscal second quarter.
ACT appoints MIT big shot Langer to board | Personnel Moves
Advanced Cell Technology (OTC:ACTC) appointed MIT professor and bioengineering legend Bob Langer to its board of directors, tapping him to lead its science advisory committee.
Langer has authored more than 1,100 journal articles, has more than 800 issued and pending patents and won the 2011 Warren Alpert Foundation Prize for bioengineering pioneers thanks to his work in drug delivery and tissue engineering.
Mauna Kea Technologies makes a management shift
Mauna Kea Technologies Announces Key Management Changes to Accelerate the Commercial Deployment of Cellvizio® in North America
Thierry Thaure Appointed Chief Executive Officer of the Company’s North American Subsidiary; Chris Tihansky Named Executive Vice President, Corporate Development
PARIS–(Marketwire – Oct 4, 2011) – Mauna Kea Technologies (EURONEXT PARIS: MKEA), the leader in the endomicroscopy market, today announced that it has named medical device industry veteran Thierry Thaure Chief Executive Officer of its North American subsidiary. Former North American President Chris Tihansky will lead the company’s expansion efforts as Executive Vice President, Corporate Development.
MIT’s Langer wins Alpert Prize | Personnel Moves
Bob Langer, MIT professor and bioengineering hot-shot, was chosen to recieve the 2011 Alpert Prize for his advancements in drug delivery and tissue engineering.
Mauna Kea Technologies appoints new human resouces director
Mauna Kea Technologies Appoints Agnès Rouffiac as Human Resources Director
PARIS–(Marketwire – Sep 13, 2011) – Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the endomicroscopy market, today announced the appointment of Agnès Rouffiac as Director, Human Resources.
With her 20 years of experience in sales, marketing and human resource (HR) management, Ms. Rouffiac will strengthen Mauna Kea Technologies’ international HR strategy.
Baxter’s Artiss sealant wins FDA clearance for face-lift procedures | Regulatory Roundup
Baxter International Inc. (NYSE: BAX) won an expanded indication for its Artiss fibrin sealant, making it available for use during in sealing tissue flaps during face-lift surgeries.
Artiss first won FDA clearance in 2008 for use in adhering skin grafts in wound beds prepared for treating burns in adults and children over the age of one.
Optos gains on Project Daytona FDA clearance | MassDevice.com Regulatory Roundup
Shares of Optos plc (LSE:OPTS) gained 6.4 percent after the company announced that the FDA granted 510(k) clearance in the U.S. for its Project Daytona retinal scanning device.
The British ophthalmology device maker’s stock closed at £1.62 today (about $2.64), up about 15 cents since August 25, the day before the clearance announcement, when OPTS shares closed at £1.52 ($2.49) on the London Stock Exchange.
Mauna Kea beats expectations, closes $70 million IPO
Mauna Kea Technologies announced a successful initial public offering, beating its projections to close at just over $70 million.
The offering closed July 4, right on schedule, and its global placement was more than five times oversubscribed. Trading begins on the NYSE Euronext in Paris today in the form of promises of shares.
Mauna Kea looks to fetch $67 million from IPO
Mauna Kea Technologies is looking to raise up to $67 million through an initial public offering of 3.29 million shares on the NYSE Euronext stock exchange.
The offering will priced between 10.65 euros and 13 euros a share and is expected to close on July 4, according to Reuters news service .